Crossmark

Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2′, 2′-Difluorodeoxycytidine After Oral Administration

Crossref DOI link: https://doi.org/10.1208/s12249-020-1617-3

Published Online: 2020-01-22

Published Print: 2020-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Valdes, Solange A.

Alzhrani, Riyad F.

Lansakara-P, Dharmika S. P.

Cui, Zhengrong
License Information

Text and Data Mining valid from 2020-01-22

Version of Record valid from 2020-01-22
More Information

Article History

Received: 20 August 2019

Accepted: 26 December 2019

First Online: 22 January 2020

Compliance with Ethical Standards

: The Institutional Animal Care and Use Committee at The University of Texas at Austin approved the animal protocol.

: ZC was a consultant to CBM Biopharma, Inc., which licensed DHA-dFdC from The University of Texas System Board of Reagents. The terms of this arrangement have been reviewed and approved by UT Austin in accordance with its policy on objectivity in research.

Document is current

Any future updates will be listed below